Neurocrine Biosciences · Health Care
NBIX
$170.88
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992.神经内分泌生物科学公司是一家美国生物制药公司，成立于1992年。
Mixed profile混合特征
Large cap大盘
$17B
Engine stance引擎立场2026-07-20
Constructive — building a base建设性 — 正在筑底
The bottoming setup is not yet confirmed (price still below the 10-day average) and the 3-day/weekly momentum is rolling筑底形态尚未确认（价格仍位于 10 日均线下方），且3 日/周线动量已开始掉头向下——动量在形态完成前已开始衰竭。等待价格收复 10 日均线且动量趋于稳定后再考虑建仓。
Key Statistics关键统计
Price价格
$170.88
5.4% below 52-week high低于52周高点 5.4%
Market Cap市值
$17B
Normal volume正常成交量
P/E Ratio市盈率
35.7x
28.9x sector median
Beta贝塔
0.69
Moves about 0.7x the market波动幅度约为市场的 0.7 倍
RSI (14)RSI（14）
55
Neutral zone中性区域
Next Earnings下次财报
2026-07-29 (10d)
Volatility Rank波动率分位
23th pctile
hist. vol. percentile历史波动率分位数
Short Interest空头兴趣
5.5% of float
Performance价格表现
| Period周期 | NBIX | S&P 500 | vs Index对比指数 |
|---|---|---|---|
| 1 Week近1周 | -3.5% | -1.5% | Lagged the index by 2.0 points落后指数 2.0 个百分点 |
| 1 Month近1月 | +7.5% | +0.6% | Beat the index by 6.9 points跑赢指数 6.9 个百分点 |
| 3 Months近3月 | +28.2% | +4.7% | Beat the index by 23.5 points跑赢指数 23.5 个百分点 |
| 6 Months近6月 | +29.1% | +7.8% | Beat the index by 21.3 points跑赢指数 21.3 个百分点 |
| Year to date年初至今 | +21.5% | +9.1% | Beat the index by 12.4 points跑赢指数 12.4 个百分点 |
| 1 Year近1年 | +27.4% | +19.4% | Beat the index by 8.0 points跑赢指数 8.0 个百分点 |
| 3 Years近3年 | +75.8% | +69.4% | Beat the index by 6.4 points跑赢指数 6.4 个百分点 |
Technicals技术面
RSI (14)RSI（14）
55
Neutral zone中性区域
vs 50-day相对50日均线
+4.9% vs 50-day avg
vs 200-day相对200日均线
+18.7% vs 200-day avg
Volatility rank波动率分位
23th percentile 分位
Engine reference levels — not advice引擎参考水平 — 非投资建议
Buy zone买入区间
$170.40
Don't chase above不追高于
$170.90
Stop止损
$156.40
Extended — wait for a pullback过度拉伸 — 等待回撤
Earnings财务业绩
10
days until next report天后公布财报
2026-07-29
Estimates being raised — 1 analysts预期上调 — 1 位分析师
Earnings call transcripts — coming soon财报电话会议记录 — 即将上线
Valuation估值
| Multiple指标 | NBIX | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（历史） | 35.74x | 28.92 | 34% |
| P/B市净率 | 5.26x | 3.52 | 30% |
| P/S市销率 | 5.98x | 3.02 | 25% |
| Earnings yield盈利收益率 | 2.80% | 2.72 | 51% |
| FCF yield自由现金流收益率 | 4.38% | 3.94 | 56% |
| Shareholder yield股东收益率 | 0.98% | 1.89 | 33% |
| EV/EBITDA企业价值/EBITDA | 25.41x | 18.21 | 29% |
| P/FCF市值/自由现金流 | 22.85x | 22.42 | 48% |
Analyst price targets — coming soon分析师目标价 — 即将上线
Financials财务数据
Revenue营业收入
5yr CAGR5年复合增速: 22.3%
Earnings Per Share每股收益
5yr CAGR5年复合增速: 2.3%
Free Cash Flow自由现金流
Margins利润率
14.7%Return on Equity股本回报率
10.3%Return on Assets资产回报率
Leverage杠杆
| Net debt / EBITDA净债务/EBITDA | -1.11 |
| Current ratio流动比率 | 3.39 |
Capital Allocation资本配置
| Buybacks (TTM)回购（TTM） | $167.7M |
| Stock-based comp股权薪酬 | $217.9M |
| Share count change (1y)股数变化（1年） | +0.7% |
Piotroski皮奥特罗斯基 4/8
Altman Z阿尔特曼Z: safe (9.1)
Watch关注
Snapshot Gauges综合指标
Valuation vs Sector估值相对行业
Roughly fair vs sector相对行业估值合理
Cheaper than 35% of its sector on blended multiples综合估值倍数低于行业内 35% 的公司
Beta市场敏感度
0.69×
0.21×3×
Moves about 0.7× the market波动幅度约为市场的 0.7 倍
Financial Health财务健康
4/8
Altman阿尔特曼: safe
Weak financial health财务健康状况偏弱
Dividend分红
—
Does not pay a dividend不派发股息
Why Is It Moving为何波动
Macro宏观
Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓
Insider cluster activity内部人集中交易
Technical技术面
NBIX took relative-strength leadershipNBIX 取得相对强弱领先
Ownership & Smart Money持仓与聪明钱
Insider activity内部人员活动: -$14.6M net (0 buyers, 7 sellers)-$14.6M 净值（0 买家，7 卖家）
Concentrated ownership集中持仓
| Fund基金 | Grade评级 | Activity动作 | % of portfolio组合占比 | As of截至 |
|---|---|---|---|---|
| RTW Investments | B | Holding持有 | 1.4% | 2026-03-31 |
| Perceptive Advisors | A | trimtrim | 0.2% | 2026-03-31 |
Signal History信号历史
TURN SIGNALED
BOTTOMING
Jul 17, 2026
NBIX took relative-strength leadershipNBIX 取得相对强弱领先
Relative strength vs SPY crossed above the 90th percentile of the last 90 days — leadership tends to persist. $170.88.相对标普500的强弱上穿近90日的第90百分位 — 领先往往延续。$170.88。
Jul 14, 2026
NBIX daily MACD crossed downNBIX 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $172.04.日线MACD柱状图转负 — 快速且嘈杂，仅作背景。$172.04。
Jul 7, 2026
BOTTOMING → NEARING A HIGH筑底中 → 接近高点
TAKE PROFITS止盈
Jul 7, 2026
NBIX RSI reached overboughtNBIX RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $177.49.RSI(14)上穿70 — 上行过度；仅作背景，单独不构成择时。$177.49。
Jul 2, 2026
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP买入预备
Jul 2, 2026
NBIX made a new 52-week highNBIX 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $174.26.价格创出52周新高 — 全市场关注的动量/趋势极值。$174.26。
Jul 1, 2026
BOTTOMING → NEARING A HIGH筑底中 → 接近高点
TAKE PROFITS止盈
Jun 29, 2026
NBIX daily MACD crossed upNBIX 日线MACD上穿
The daily MACD histogram turned positive — fast and noisy, context rather than a standalone trigger. $170.00.日线MACD柱状图转正 — 快速且嘈杂，仅作背景。$170.00。
Jun 26, 2026
NBIX made a new 52-week highNBIX 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $168.52.价格创出52周新高 — 全市场关注的动量/趋势极值。$168.52。
Showing last 15 of显示最近15条，共 255 signals条信号
Factor Profile因子特征
Composite factor score综合因子得分: -0.32
Value价值
-0.7
Quality质量
+0.4
Investment资本投入
-0.9
Shareholder payout股东回报
-0.8
Low volatility低波动
+0.5
Low market beta低市场敏感度
+0.2
Earnings quality盈利质量
+0.4
Short interest空头兴趣
-0.1
Company Profile公司档案
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992.神经内分泌生物科学公司是一家美国生物制药公司，成立于1992年。
Watch items — what could change the thesis关注项 — 可能改变论点的因素
- Margin compression despite revenue growth
- Receivables stretch
Get the full picture获取完整视图
Nightly signals, options flow, and factor analysis across all S&P 500 names.每日更新的信号、期权资金流向和因子分析，覆盖所有标普500成分股。